ELVN Enliven Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
11:32
Aug 18
Aug 18
JPMorgan, TD Cowen, Citigroup, Jefferies, and other firms raised price targets on twelve stocks.
JPMorgan, TD Cowen, Citigroup, Jefferies, and other firms raised price targets on twelve stocks while cutting targets on six others and initiating or resuming coverage on six additional names.
12:53
Aug 17
Aug 17
Reports widest ownership across specialist funds
"Reports widest Q2 2026 ownership across 95 specialist funds based on 13F filings, no directional view."
MED
12:49
Aug 17
Aug 17
Reports most added positions across funds
"Reports most added positions across specialist funds from Q1 to Q2 2026, no directional view."
MED
11:58
Aug 17
Aug 17
Reports widest Q2 ownership among specialist funds
Reports the widest Q2 2026 ownership across 93 specialist funds based on 13F filings.
MED
11:50
Aug 17
Aug 17
Reports most added positions by specialist funds
Reports the most added positions by specialist funds from Q1 to Q2 2026.
MED
11:28
Aug 17
Aug 17
A news wire reports a broad list of price target cuts across multiple sectors by various banks.
A news wire reports a broad list of price target cuts across multiple sectors by various banks, alongside several coverage initiations and resumptions with new price targets, all without expressing any personal market view.
23:02
Aug 03
Aug 03
Four biotechs flagged as potential buyout targets
Author flags VRDN, OKUR, ELVN, and EWTX as potential acquisition targets based on Novartis Denver flight activity; notes ELVN HQ move and suspicious price action, but no directional commitment.
LOW
22:56
Aug 03
Aug 03
Denver flights flag potential biotech M&A targets
Flags four biotechs as possible M&A targets from Novartis's unusual Denver flight activity; notes ELVN is the one already moving.
LOW
13:13
Jun 21
Jun 21
Author lists ELVN and CYTK as early-stage M&A candidates (<2 months post positive data).
Author lists ELVN and CYTK as early-stage M&A candidates (<2 months post positive data), too early in the author's own framework but flagged as names to monitor for future rotation into the hot zone.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom.
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
05:02
Jun 15
Jun 15
Author endorses ELVN as a bullish candidate in the context of M&A activity.
Author endorses ELVN as a bullish candidate in the context of M&A activity, drawing a parallel to TERN which attracted multiple bidders before being acquired by MRK, suggesting ELVN may be a similar takeout target.
MED
About ELVN Analyst Coverage
Buzzberg tracks ELVN (Enliven Therapeutics, Inc.) across 2 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 11 total trade ideas tracked. Past 7 days: 6 watch. Latest voices: DeItaone, seedy19tron.